Patients, indications, and protocol
| Patient no. . | Sex . | Body weight (Kg) . | Indicationa . | Injected doseb MBq . | Delay antibody/111 In-tracer (days) . | Delay111 In-tracer/RIGS (days) . |
|---|---|---|---|---|---|---|
| 1 | F | 78 | A | 133 | 3 | 4 |
| 2 | F | 76 | A | 215 | 4 | 3 |
| 3 | F | 68 | B | 178 | 5 | 2 |
| 4 | M | 70 | B | 148 | 3 | 4 |
| 5 | F | 53 | B | 326 | 4 | 3 |
| 6 | F | 66 | B | 303 | 3 | 2 |
| 7 | F | 65 | C | 263 | 4 | NDc |
| 8 | F | 62 | C | 118 | 5 | 2 |
| 9 | F | 64 | C | 155 | 4 | 3 |
| 10 | F | 50 | C | 303 | 4 | 3 |
| 11 | F | 40 | C | 157 | 4 | 3 |
| 12 | M | 83 | C | 173 | 4 | 3 |
| 13 | F | 55 | B | 178 | 4 | 3 |
| Patient no. . | Sex . | Body weight (Kg) . | Indicationa . | Injected doseb MBq . | Delay antibody/111 In-tracer (days) . | Delay111 In-tracer/RIGS (days) . |
|---|---|---|---|---|---|---|
| 1 | F | 78 | A | 133 | 3 | 4 |
| 2 | F | 76 | A | 215 | 4 | 3 |
| 3 | F | 68 | B | 178 | 5 | 2 |
| 4 | M | 70 | B | 148 | 3 | 4 |
| 5 | F | 53 | B | 326 | 4 | 3 |
| 6 | F | 66 | B | 303 | 3 | 2 |
| 7 | F | 65 | C | 263 | 4 | NDc |
| 8 | F | 62 | C | 118 | 5 | 2 |
| 9 | F | 64 | C | 155 | 4 | 3 |
| 10 | F | 50 | C | 303 | 4 | 3 |
| 11 | F | 40 | C | 157 | 4 | 3 |
| 12 | M | 83 | C | 173 | 4 | 3 |
| 13 | F | 55 | B | 178 | 4 | 3 |
For each patient, the presence of unknown metastases was suspected: A, patients submitted to first surgery for thyroidectomy and bilateral lymph node dissection; B,second surgery in the absence of previous bilateral lymph node dissection; and C, surgery when bilateral lymph node dissection was performed during the first surgery.
The bispecific antibody dose was 0.1 mg/kg body weight.
ND, not done.